November 3, 2016
TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, will be addressing delegates at Pharmaceutical Serialisation & Traceability 2016, taking place November 7 - 9, in Geneva, Switzerland.
Jean-Marie Aulnette, vice president of EMEA, TraceLink, will discuss key success factors to consider when implementing a global serialisation strategy. The presentation will take place on Wednesday, November 9 at 13:30 p.m. CEST.
The EU Falsified Medicines Directive (FMD) introduces complex safety features for pharmaceutical companies, parallel importers, wholesalers, and pharmacies that sell or dispense products into the European Union. The law requires unit-level serialisation, compliance reporting, and verification to go into effect by February 2019. As part of the regulation, all serialised data must be sent to the centralized EU Hub and then passed through to the national repositories within the individual EU countries.
To date, 39 pharmaceutical manufacturers with EU FMD requirements have chosen the Life Sciences Cloud, giving them single-integration access to an EMVO-tested, compliance solution that will help eliminate business risk and ensure drug products reach patients in the most timely and cost-effective manner. Two years ahead of the February 2019 deadline, TraceLink has already processed compliance reports for 227,034 units of product into the EU Hub for its customers that are live on the network and meeting EU FMD compliance regulations.
Learn more about the EU FMD requirements and TraceLink’s real-time experience with the EU Hub at this year’s Pharmaceutical Serialisation & Traceability meeting. Schedule a free onsite serialisation consultation with a TraceLink compliance expert and receive custom guidance on how to move your company’s serialization strategy forward in the EU, and globally.